JP
JAZZ icon

John Paulson’s Jazz Pharmaceuticals JAZZ Stock Holding History

John Paulson’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-963,000
Closed -$88.6M – 90
2013
Q3 		$88.6M Hold
963,000
– – 0.57% 43
2013
Q2 		$66.2M Buy
+963,000
New +$58.9M 0.47% 49

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.62B AUM 39.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

John Paulson's JAZZ Position: Q4 2013 in Review

John Paulson sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2013, closing a stake of 963,000 shares — an estimated $88.6M sold.

John Paulson first reported a position in JAZZ in Q2 2013 and held it in 2 quarters. The position peaked at $88.6M in Q3 2013. 280 funds tracked by Wall St. Rank hold JAZZ as of Q4 2013.

  • John Paulson reported no remaining Jazz Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • John Paulson sold 963,000 Jazz Pharmaceuticals shares in Q4 2013, an estimated $88.6M.
  • John Paulson first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • John Paulson's Jazz Pharmaceuticals position peaked at $88.6M in Q3 2013.
  • 280 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2013.

Based on Paulson & Co's 13F filing for Q4 2013, filed 14 Feb 2014.